...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicinski Glasnik >The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia – single institution experience
【24h】

The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia – single institution experience

机译：可溶性fms样酪氨酸激酶1（sFLT-1）与胎盘生长因子（PLGF）的比率可作为先兆子痫严重程度的可能指标–单一机构的经验

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim To investigate a potential of the clinical use of the solublefms-like tyrosine kinase 1 (sFLT-1) to placental growth factor(PlGF) ratio from the perspective of a small hospital centre.Methods Maternal serum samples were analysed at 241/7-28 0/7,and 281/7-320/7 weeks of gestation. The level of sFLT-1 and PIGFwas determined by immunoassay platform and used to calculatethe sFLT-1/PIGF ratio in 35 pregnant women, and divided intosubgroups according to preeclampsia occurrence at the time of delivery:preterm (≤37 weeks) or term (37-42 weeks’), and matcheda control group.Results Patients in the preterm delivery group had a significantlyhigher incidence of intrauterine growth restriction, lower gestationalage at the time of delivery, and lower infant birth weight comparedto the other two groups. There was a negative correlationbetween the sFLT-1/PlGF ratio and GA and between the sFLT-1/PlGF ratio and birth weight at the time of delivery. The value ofthe sFLT-1/PlGF ratio was significantly higher in the preterm deliveryPE group. All the PE group pregnancies ended with caesareandelivery compared to 25% in the control group. However, none ofthe patients from the PE group had any of the possible complicationsof preeclampsia nor did they require additional therapy such asblood transfusion or additional non-standard hypertensive therapy.Conclusion The sFLT-1/PlGF ratio could be used as an indicatorfor the development and estimation of the severity of PE toprovide objective evidence for the management of preeclampsiapatients, and as a predictive marker of preeclampsia at low cost.
机译：目的从小型医院中心的角度探讨可溶性fms样酪氨酸激酶1（sFLT-1）与胎盘生长因子（PlGF）之比的临床应用潜力。方法在241 / 7- 28 0/7，和281 / 7-320 / 7孕周。通过免疫测定平台测定sFLT-1和PIGF的水平，并用于计算35名孕妇的sFLT-1 / PIGF比率，并根据分娩时先兆子痫的发生将其分为亚组：早产（≤37周）或足月（37）结果-42周），并与对照组相匹配。结果与其他两组相比，早产组的子宫内生长受限发生率明显高，分娩时的胎龄较低，婴儿出生体重较低。 sFLT-1 / PlGF比值与GA之间以及sFLT-1 / PlGF比值与分娩时出生体重之间呈负相关。在早产PE组中，sFLT-1 / PlGF比值明显更高。 PE组的所有妊娠均以剖腹产结束，而对照组为25％。然而，PE组的患者均无先兆子痫的任何可能并发症，也不需要其他疗法，例如输血或其他非标准的高血压疗法。结论sFLT-1 / PlGF比值可作为发展和发展的指标。评估PE的严重程度可为先兆子痫患者的治疗提供客观证据，并作为低成本先兆子痫的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号